Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
NCT ID: NCT05589974
Last Updated: 2024-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2022-10-01
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OCT in Rare Chorioretinal Diseases
NCT02141308
Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC)
NCT03950089
OCT Angio in Cerebral Small Vessel Disease
NCT05052788
Green Subthreshold Laser Therapy for Chronic Central Serous Chorioretinopathy.
NCT07020793
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
NCT00211445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute
Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months.
No interventions assigned to this group
Chronic
Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months.
Verteporfin
Chronic CSC are receiving one treatment before the observation period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Verteporfin
Chronic CSC are receiving one treatment before the observation period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Possible to obtain fundus imaging
* Acute CSC ˂4 months of duration in one eye, defined as:
1. Subfoveal presence of SRF on OCT
2. Present attack is 1st -3rd attack of CSC
b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT
* Chronic CSC ≥4 months of duration in one eye, defined as:
1. Subfoveal presence of SRF on OCT
2. Subjective visual loss/symptoms
3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT
4. Patient history and examination consistent with chronic CSC
Exclusion Criteria
* Contraindications for FA, ICGA or PDT (only for chronic CSC)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helse Stavanger HF
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vegard Forsaa, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Helse Stavanger HF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stavanger University Hospital, Department of Ophthalmology
Stavanger, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REK485079
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.